ongoing trials trial from other registries Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis - - RECRUITING Year: 2024 Date: new Author: Source https://clinicaltrials.gov/study/NCT06429176 Participants 15 patients 0-17 years with Cystic Fibrosis Interventions VX-770 50mg, VX-770 granules, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 granules, VX-445/VX-661/VX-770 fixed-dose combination granules, Ivacaftor 25 mg granules, Kalydeco 59.5 mg granules in sachet, VX-770 75mg, Kaftrio 60 mg/40 mg/80 mg granules in sachet, Kalydeco 50 mg granules in sachet, Kaftrio 75 mg/50 mg/100 mg granules in sachet, VX-445/VX-661/VX-770 granules, Kalydeco 25 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules Outcome measures Safety and tolerability assessments as determined by adverse events (AEs), clinical laboratory values, standard 12-lead ECGs, vital signs, and pulse oximetry